EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

In Vivo Engineered CAR-T Cell Therapy: Lessons Built from COVID-19 mRNA Vaccines

Sikun Meng iD, Tomoaki Hara, Yutaka Miura iD, Yasuko Arao, Yoshiko Saito, Kana Inoue, Takaaki Hirotsu iD, Andrea Vecchione iD, Taroh Satoh iD, Hideshi Ishii iD

International Journal of Molecular Sciences · 28.03.2025 · 26 (7) · 3119

DOI: 10.3390/ijms26073119 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.03.2025. Verfasst von Sikun Meng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Data Science, Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Yamadaoka …. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, COVID-19 Vaccines, COVID-19, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology, Japan Agency for Medical Research and Development, Princess Takamatsu Cancer Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized cancer immunotherapy but continues to face significant challenges that limit its broader application, such as antigen targeting, the tumor microenvironment, and cell persistence, especially in solid tumors. Meanwhile, the global implementation of mRNA vaccines during the COVID-19 pandemic has highlighted the transformative potential of mRNA and lipid nanoparticle (LNP) technologies. These innovations, characterized by their swift development timelines, precise antigen design, and efficient delivery mechanisms, provide a promising framework to address some limitations of CAR-T therapy. Recent advancements, including mRNA-based CAR engineering and optimized LNP delivery, have demonstrated the capacity to enhance CAR-T efficacy, particularly in the context of solid tumors. This review explores how mRNA-LNP technology can drive the development of in vivo engineered CAR-T therapies to address current limitations and discusses future directions, including advancements in mRNA design, LNP optimization, and strategies for improving in vivo CAR-T functionality and safety. By bridging these technological insights, CAR-T therapy may evolve into a versatile and accessible treatment paradigm across diverse oncological landscapes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveCOVID-19 VaccinesCOVID-19Receptors, Chimeric AntigenNeoplasmsHumansSARS-CoV-2NanoparticlesRNA, MessengermRNA VaccinesAnimalsVaccines, SyntheticLipidsLiposomes

Stichwörter der Autor:innen

CAR-T therapyimmune response regulationlipid nanoparticlesmRNA technologymRNA vaccines

Substanzen

COVID-19 VaccinesReceptors, Chimeric AntigenRNA, MessengermRNA VaccinesLipid NanoparticlesVaccines, SyntheticLipidsLiposomes

Autor:innen und Institutionen

  • Department of Medical Data Science, Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka 565-0871, Japan.
  • Laboratory for Chemistry and Life Science, Institute of Integrated Research, Institute of Science Tokyo, 4259 Nagatsutacho, Midori-ku, Yokohama 226-8501, Japan.
  • Hirotsu Bio Science Inc., Chiyoda-Ku, Tokyo 102-0094, Japan.
  • Department of Clinical and Molecular Medicine, University of Rome "Sapienza", Santo Andrea Hospital, Via di Grottarossa, 1035, 00189 Rome, Italy.
  • Center for Cancer Genomics and Precision Medicine, Osaka University Hospital, Yamadaoka 2-2, Suita, Osaka 565-0871, Japan.

ORCID-Profile: Sikun Meng, Yutaka Miura, Takaaki Hirotsu, Andrea Vecchione, Taroh Satoh, Hideshi Ishii

Förderung

  • Ministry of Education, Culture, Sports, Science and Technology
  • Japan Agency for Medical Research and Development
  • Princess Takamatsu Cancer Research Fund
  • IFO Research Communications
  • Oceanic Wellness Foundation
  • Suzuken Memorial Foundation
  • Clinical Research Promotion Foundation

Zitieren

APA

Meng, S., Hara, T., Miura, Y., Arao, Y., Saito, Y., Inoue, K., Hirotsu, T., Vecchione, A., Satoh, T., & Ishii, H. (2025). In Vivo Engineered CAR-T Cell Therapy: Lessons Built from COVID-19 mRNA Vaccines. International Journal of Molecular Sciences, 26(7), 3119. https://doi.org/10.3390/ijms26073119

Vancouver

Meng S, Hara T, Miura Y, Arao Y, Saito Y, Inoue K, et al. In Vivo Engineered CAR-T Cell Therapy: Lessons Built from COVID-19 mRNA Vaccines. International Journal of Molecular Sciences. 2025;26(7):3119. doi:10.3390/ijms26073119

BibTeX
@article{Meng2025,
  author = {Meng, Sikun and Hara, Tomoaki and Miura, Yutaka and Arao, Yasuko and Saito, Yoshiko and Inoue, Kana and Hirotsu, Takaaki and Vecchione, Andrea and Satoh, Taroh and Ishii, Hideshi},
  title = {In Vivo Engineered CAR-T Cell Therapy: Lessons Built from COVID-19 mRNA Vaccines},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {7},
  pages = {3119},
  doi = {10.3390/ijms26073119}
}
Kostenlos starten →